Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Castle Biosciences (NASDAQ: CSTL), a healthcare company focused on innovative diagnostic testing, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's executive management will deliver a corporate presentation on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. Investors and interested parties can access the live audio webcast through Castle Biosciences' investor relations website, with a replay available after the presentation.
Castle Biosciences (NASDAQ: CSTL), un'azienda sanitaria specializzata in test diagnostici innovativi, ha annunciato la sua partecipazione alla 2025 Jefferies Global Healthcare Conference. Il management esecutivo dell'azienda terrà una presentazione aziendale il mercoledì 4 giugno 2025, alle 7:35 ora orientale. Investitori e interessati potranno seguire la diretta audio in streaming sul sito web delle relazioni con gli investitori di Castle Biosciences, con la possibilità di rivedere la registrazione dopo la presentazione.
Castle Biosciences (NASDAQ: CSTL), una empresa de salud centrada en pruebas diagnósticas innovadoras, ha anunciado su participación en la próxima Conferencia Global de Salud Jefferies 2025. La dirección ejecutiva de la compañía realizará una presentación corporativa el miércoles 4 de junio de 2025 a las 7:35 a.m., hora del Este. Los inversores y partes interesadas podrán acceder a la transmisión de audio en vivo a través del sitio web de relaciones con inversores de Castle Biosciences, con una repetición disponible después de la presentación.
Castle Biosciences (NASDAQ: CSTL)는 혁신적인 진단 검사에 중점을 둔 헬스케어 회사로, 다가오는 2025 Jefferies 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2025년 6월 4일 수요일 동부 시간 오전 7시 35분에 기업 프레젠테이션을 진행할 예정입니다. 투자자 및 관심 있는 분들은 Castle Biosciences 투자자 관계 웹사이트를 통해 라이브 오디오 웹캐스트에 접속할 수 있으며, 프레젠테이션 후 재방송도 제공됩니다.
Castle Biosciences (NASDAQ : CSTL), une entreprise de santé spécialisée dans les tests diagnostiques innovants, a annoncé sa participation à la 2025 Jefferies Global Healthcare Conference. La direction exécutive de la société présentera une conférence d'entreprise le mercredi 4 juin 2025 à 7h35, heure de l'Est. Les investisseurs et parties intéressées pourront accéder à la diffusion audio en direct via le site web des relations investisseurs de Castle Biosciences, avec un replay disponible après la présentation.
Castle Biosciences (NASDAQ: CSTL), ein auf innovative diagnostische Tests spezialisiertes Gesundheitsunternehmen, hat seine Teilnahme an der bevorstehenden 2025 Jefferies Global Healthcare Conference angekündigt. Das Führungsteam des Unternehmens wird am Mittwoch, den 4. Juni 2025, um 7:35 Uhr Eastern Time eine Unternehmenspräsentation halten. Investoren und Interessierte können den Live-Audio-Webcast über die Investor-Relations-Website von Castle Biosciences verfolgen; eine Wiederholung steht nach der Präsentation zur Verfügung.
- None.
- None.
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When is Castle Biosciences (CSTL) presenting at the 2025 Jefferies Healthcare Conference?
How can I watch Castle Biosciences' (CSTL) presentation at the Jefferies Conference?
What does Castle Biosciences (CSTL) do as a company?
